Publication Author: Basu_Anirban

• Generalized modeling approaches to risk adjustment of skewed outcomes data.

  Manning WG, Basu A, Mullahy J. Generalized modeling approaches to risk adjustment of skewed outcomes data. J Health Econ. 2005 May;24(3):465-88.

  rakerr2

  May 1, 2005

• Estimating marginal and incremental effects on health outcomes using flexible link and variance function models.

  Basu A, Rathouz PJ. Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. Biostatistics. 2005 Jan;6(1):93-109.

  rakerr2

  January 1, 2005

• Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues.

  Basu A. Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues. Schizophr Res. 2004 Dec 1;71(2-3):445-62. Review.

  rakerr2

  December 1, 2004

• Comparing alternative models: log vs Cox proportional hazard?

  Basu A, Manning WG, Mullahy J. Comparing alternative models: log vs Cox proportional hazard? Health Econ. 2004 Aug;13(8):749-65.

  rakerr2

  August 1, 2004

• Impact of hormone therapy when combined with external beam radiotherapy for early-stage, intermediate-, or high-risk prostate cancer.

  Jani AB, Basu A, Abdalla I, Connell PP, Krauz L, Vijayakumar S. Impact of hormone therapy when combined with external beam radiotherapy for early-stage, intermediate-, or high-risk prostate cancer. Am J Clin Oncol. 2003 Aug;26(4):382-5.

  rakerr2

  August 1, 2003

• Sentinel lymph node versus axillary lymph node dissection for early-stage breast carcinoma: a comparison using a utility-adjusted number needed to treat analysis.

  Jani AB, Basu A, Heimann R, Hellman S. Sentinel lymph node versus axillary lymph node dissection for early-stage breast carcinoma: a comparison using a utility-adjusted number needed to treat analysis. Cancer. 2003 Jan 15;97(2):359-66.

  rakerr2

  January 15, 2003

• Does competition under Medicare Prospective Payment selectively reduce expenditures on high-cost patients?

  Meltzer D, Chung J, Basu A. Does competition under Medicare Prospective Payment selectively reduce expenditures on high-cost patients? Rand J Econ. 2002 Autumn;33(3):447-68.

  rakerr2

  October 1, 2002

• An evidence-based analysis of the management of localized prostate cancer.

  Abdalla I, Basu A, Hellman S. An evidence-based analysis of the management of localized prostate cancer. Cancer J. 2002 Jan-Feb;8(1):40-6.

  rakerr2

  January 1, 2002